INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Public ClinicalTrials.gov record NCT04455841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Study identification
- NCT ID
- NCT04455841
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 84 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2021 (Actual)
- Primary completion
- Apr 1, 2025 (Actual)
- Completion
- Sep 8, 2026 (Actual)
- Last update posted
- Oct 1, 2026
2021 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope Orange County | Irvine | California | 92618 | — |
| Usc Norris Comprehensive Cancer Center | Los Angeles | California | 90089 | — |
| Stanford Cancer Center | Palo Alto | California | 94304 | — |
| Prebys Cancer Center | San Diego | California | 92103 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Emory University-Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Start Midwest | Grand Rapids | Michigan | 49546 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Weill Cornell Medical Centers | New York | New York | 10065 | — |
| Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy | Durham | North Carolina | 27705 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04455841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04455841 live on ClinicalTrials.gov.